Table 2

Achievement of therapeutic targets among guselkumab-randomised patients over time (NRI)

Guselkumab 100 mg Q4WGuselkumab 100 mg Q8W
 Week81624521008162452100
DAPSA
 LDA (≤14)43 (18)61 (25)88 (36)125 (51)151 (62)43 (17)79 (32)97 (39)130 (52)147 (59)
 Remission (≤4)5 (2)12 (5)21 (9)39 (16)52 (21)3 (1)15 (6)23 (9)46 (19)60 (24)
cDAPSA
 LDA (≤13)*41 (17)58 (24)89 (36)125 (51)150 (61)44 (18)75 (30)95 (38)131 (53)147 (60)
 Remission (≤4)5 (2)13 (5)29 (12)44 (18)59 (24)4 (2)19 (8)25 (10)53 (21)65 (26)
Enthesitis resolution45 (27)66 (40)71 (43)93 (56)102 (61)50 (32)75 (48)87 (55)97 (62)110 (70)
Dactylitis resolution39 (32)64 (53)80 (66)90 (74)87 (72)34 (31)51 (46)66 (59)86 (77)92 (83)
Skin response
 PASI 90‡§100 (54)114 (62)142 (77)136 (74)97 (55)121 (69)131 (74)123 (70)
 PASI 100‡§62 (34)83 (45)106 (58)109 (59)48 (27)80 (45)93 (53)94 (53)
 IGA 0/1 response‡§¶122 (66)127 (69)147 (80)140 (76)110 (62)124 (70)131 (74)126 (72)
 Skin VAS ≤15 mm§**26 (14)58 (32)68 (37)93 (51)96 (53)38 (22)61 (36)71 (42)88 (52)95 (56)
PASDAS
 LDA (≤3.2)25 (10)44 (18)58 (24)105 (43)126 (51)28 (11)56 (23)76 (31)106 (43)122 (49)
 Remission (≤1.9)4 (2)11 (4)22 (9)36 (15)51 (21)2 (1)16 (6)23 (9)52 (21)58 (23)
MDA*8 (3)33 (14)47 (19)83 (34)93 (38)9 (4)42 (17)63 (25)77 (31)100 (40)
Absolute change in response rate from previous visit
±1 to <5+5 to <10+10 to <15+15 to <20≥20
  • Number (%) of guselkumab-randomised patients (N=493) achieving therapeutic endpoints over time (NRI) are shown.

  • *Excludes patients who achieved endpoint at baseline.

  • †Among patients with domain at baseline.

  • ‡PASI and IGA not assessed at Week 8.

  • §Among patients with baseline BSA ≥3% and IGA ≥2 .

  • ¶IGA skin response=score of 0 or 1 and ≥2 grade improvement from baseline.

  • **Patients with Skin VAS >15mm at baseline.

  • BSA, body surface area; cDAPSA, clinical Disease Activity Index for Psoriatic Arthritis; DAPSA, Disease Activity Index for Psoriatic Arthritis; IGA, Investigator’s Global Assessment of psoriasis; LDA, low disease activity; MDA, minimal disease activity; NRI, non-responder imputation; PASDAS, Psoriatic Arthritis Disease Activity Score; PASI 90/100, ≥90% improvement/100% improvement in Psoriasis Area and Severity Index; Q4W, every 4 weeks; Q8W, every 8 weeks; VAS, Visual Analogue Scale.